These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis].
    Author: Mundo A, Pedone V, Lamanna G, Cervini C.
    Journal: Clin Ter; 1997; 148(1-2):7-13. PubMed ID: 9377840.
    Abstract:
    Sulphasalazine (SSZ) is now recognised to be a useful agent in the management of rheumatoid arthritis (RA). We studied SSZ toxicity (2 g/die) and duration of therapy in 102 patients with RA. Adverse events occurred in 25.4% of all patients. In all patients the reactions subsided on either discontinuation of the drug or decrease of the dose. Gastrointestinal was the most common. At 5 years of follow-up the percentage of patients treated with SSZ still on drug was 29%, the inefficacy was 40% of the total drop-out.
    [Abstract] [Full Text] [Related] [New Search]